Appendix 1.

Author Relationships With Industry and Other Entities—2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline)

Committee MemberEmploymentConsultantSpeaker's BureauOwnership/Partnership/ PrincipalPersonal ResearchInstitutional, Organizational, or Other Financial BenefitExpert Witness
R. Scott Wright, ChairMayo Clinic—Professor of Medicine and Consultant in CardiologyNoneNoneNoneNoneNoneNone
Jeffrey L. Anderson, Vice ChairIntermountain Medical Center—Associate Chief of Cardiology; University of Utah—Professor of Medicine
  • Bristol-Myers Squibb

  • Daiichi Sankyo

  • Eli Lilly

  • Sanofi-aventis

  • Schering-Plough

None
  • AstraZeneca

NoneNone
Cynthia D. AdamsCommunity Health Network/Community Heart and Vascular —Director, Network Cardiovascular Outcomes and Nursing ResearchNoneNoneNoneNoneNoneNone
Charles R. BridgesUniversity of Pennsylvania Medical Center—Associate Professor of Surgery
  • Baxter Biosurgery

  • Bayer

  • ZymoGenetics

NoneNoneNoneNone
Donald E. Casey, JrAtlantic Health—Chief Medical Officer and Vice President of QualityNoneNoneNoneNoneNoneNone
Steven M. EttingerPennsylvania State University Heart and Vascular Institute—Professor of Medicine and RadiologyNoneNoneNoneNoneNoneNone
Francis M. FesmireHeart Stroke Center—Director
  • Abbot Vascular

NoneNoneNone
  • Board of Directors, Society of Chest Pain Centers

  • 2010: Plaintiff, Missed Acute Coronary Syndromes

Theodore G. GaniatsUniversity of California, San Diego—Professor and Interim ChairNoneNoneNoneNoneNoneNone
Hani JneidBaylor College of Medicine—Assistant Professor of MedicineNoneNoneNoneNoneNoneNone
A. Michael LincoffCleveland Clinic—Vice Chairman of Cardiovascular Medicine, Director of C5Research; Professor of Medicine
  • Baxter

  • Bristol-Myers Squibb

  • Roche

  • Schering-Plough

NoneNone
  • AstraZeneca*

  • Bristol-Myers Squibb*

  • Eli Lilly*

  • Kai Pharmaceuticals*

  • Roche*

  • Sanofi-aventis*

  • Schering-Plough*

  • Takeda*

NoneNone
Eric D. PetersonDuke University Medical Center—Professor of Medicine, Director of Cardiovascular Research
  • AstraZeneca

NoneNone
  • Bristol-Myers Squibb*

  • Eli Lilly*

  • Johnson & Johnson*

  • Merck/Schering-Plough*

  • Sanofi-aventis

NoneNone
George J. PhilippidesBoston Medical Center—Vice Chair for Clinical Affairs, Cardiovascular Section; Boston University School of Medicine—Associate Professor of MedicineNoneNoneNoneNoneNoneNone
Pierre TherouxMontreal Heart Institute
  • AstraZeneca

  • Bristol-Myers Squibb

  • Eli Lilly

  • Sanofi-aventis

  • Boehringer Ingelheim

  • Bristol-Myers Squibb

  • Sanofi-aventis

None
  • Schering-Plough*

NoneNone
Nanette K. WengerEmory University School of Medicine—Professor of Medicine; Grady Memorial Hospital—Chief of Cardiology
  • AstraZeneca

  • Boston Scientific

  • Merck

  • Schering-Plough*

NoneNone
  • Eli Lilly*

  • Merck*

  • Sanofi-aventis*

NoneNone
James Patrick ZidarUniversity of North Carolina Health Systems—Clinical Professor of Medicine
  • Boston Scientific

NoneNoneNoneNoneNone
  • This table represents the relationships of committee members with industry and other entities that were reported by authors to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of $10 000 or more of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted.

  • * Significant relationship.

  • Recused from voting on Section 3.2. Recommendations for Antiplatelet and Anticoagulant Therapy, and Section 5.2.1. Recommendations for Convalescent and Long-Term Antiplatelet Therapy.

  • Relationship began after writing effort was complete but before final approval.